Sarcopenia & muscle wasting

What changes during this transition

Sarcopenia is a defined clinical disease, not a synonym for aging or weakness. The operational diagnosis uses EWGSOP2 (Cruz-Jentoft 2019) and AWGS 2019 criteria: low muscle strength (grip strength <27kg men / <16kg women), low muscle mass (DXA-confirmed appendicular lean mass below population cutoffs), and low physical performance (gait speed <0.8 m/s, SPPB <8). Prevalence climbs from ~5-10% at age 65 to 30%+ by age 80 in community-dwelling cohorts, with earlier onset in chronic illness — cancer cachexia, COPD, congestive heart failure, chronic kidney disease, post-bariatric surgery, prolonged immobilization. Sarcopenic obesity is a distinct phenotype with worse functional and mortality outcomes than either condition alone, and is increasingly the dominant clinical presentation as obesity prevalence shifts the population baseline. The standard-of-care stack for sarcopenia is lifestyle-medicine first, and the evidence gap between lifestyle and any pharmacotherapy is enormous. Resistance training 2-3x/week with progressive overload is the single most-evidence-based intervention — Liu 2020 Cochrane (n=2400+ across 32 RCTs) is the canonical reference, and no peptide on this surface approaches that evidence base. Dietary protein at 1.2-1.6 g/kg/day with leucine at the 2.5g/meal anabolic threshold (PROT-AGE 2013; ESPEN 2019 guidelines) addresses anabolic resistance in older adults. Vitamin D repletion to >30 ng/mL in confirmed deficiency is established. Testosterone replacement in hypogonadal men and estrogen replacement in postmenopausal women address the hormonal contributors. Confirmed B12 deficiency repletion via MMA + homocysteine workup is standard medicine, not peptide territory. There is no FDA-approved drug specifically for sarcopenia as of 2026. Bimagrumab (Novartis activin type II receptor antibody, non-peptide) hit body-composition surrogates in Phase 2 but failed its Phase 3 for sarcopenic obesity in 2023 on the lean-mass-to-function translation that the consensus criteria require. Anamorelin (ghrelin agonist) was approved in Japan in 2021 for cancer cachexia specifically — multi-jurisdictionally legitimate, but the cachexia indication does not propagate to general sarcopenia. The tirzepatide + bimagrumab combination program for sarcopenic obesity (Lilly's BELIEVE / Versanis-acquired program) is pipeline, not approved. The library surfaces three compounds on this stage. Tesamorelin has the strongest case in the GH-axis cluster because its FDA approval for HIV-associated lipodystrophy documented lean-mass benefit as a secondary trial finding, and its euglycemic-clamp profile distinguishes it favorably from the rest of the class in the sarcopenic-obesity / T2D overlap; sarcopenia-specific RCT data against EWGSOP2 endpoints does not exist. Ipamorelin is the cleanest selective ghrelin-receptor agonist in the class — no cortisol bump, no MK-677-style edema or CHF signal — with mechanism-aligned but RCT-absent positioning. B12-methylcobalamin addresses the most-treatable reversible contributor in this population via MMA + homocysteine workup, with a multi-jurisdictional evidence base (van Dronkelaar 2018; Hirani 2017; Japanese clinical practice) and Tier 2 confirmed-deficiency repletion status. What is NOT surfaced is editorially deliberate: MK-677 has the strongest dedicated elderly-cohort lean-mass-gain trial record (Murphy 2001, Nass 2008, Adunsky 2011), but its safety thread — a CHF signal that halted at least one elderly trial, documented edema, and marked insulin resistance — disqualifies it from primary discovery in the typical sarcopenia patient with cardiovascular and metabolic comorbidity; it lives as a substrate-only entry for honest /ask answers. Tirzepatide is substrate-only for safety education in the sarcopenic-obesity user already on a GLP-1 or dual incretin; it is not a sarcopenia therapy.